文献速递神经免疫神经重症与神经感染

单纯疱疹脑炎后自身免疫性脑炎的频率、症状、危险因素与结局:前瞻性观察研究及回顾性分析

Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.
PubMed 文献 · Lancet Neurol · 2018-07-23

这项前瞻性观察研究在西班牙19个中心纳入51例单纯疱疹脑炎患者,随访中14例(27%)发生自身免疫性脑炎且均有神经元抗体,抗体检测(3周内)为危险因素(OR 11.5)。回顾性队列48例中44例抗体确诊;≤4岁患儿起病间隔更短、运动障碍与意识下降更多、1年结局更差。

要点

  • 单纯疱疹脑炎后27%(14/51)发生自身免疫性脑炎,且均检出神经元抗体。
  • 起病3周内检出抗体是自身免疫性脑炎的危险因素(OR 11.5,95%CI 2.7-48.8)。
  • ≤4岁患儿较>4岁者起病间隔更短、舞蹈手足徐动及意识下降更多、1年改良Rankin量表评分更差。

核心结论

  • 前瞻性研究显示27%的单纯疱疹脑炎患者发生自身免疫性脑炎,与神经元抗体产生相关,多在单纯疱疹脑炎治疗后2个月内出现。
  • 症状呈年龄依赖性,幼儿神经结局更差;及时诊断重要,因患者(尤其>4岁者)可对免疫治疗有反应。

研究设计与样本

  • 前瞻性观察研究(队列A)在西班牙19个二级和三级中心纳入2014年1月1日至2017年10月31日诊断的单纯疱疹脑炎患者54例,51例纳入分析(中位年龄50岁,IQR 5-68)。
  • 回顾性分析队列B纳入2011年10月7日至2017年10月31日出现新发或加重神经症状且非单纯疱疹病毒再激活的48例患者(中位年龄8.8岁,IQR 1.1-44.2;男27例)。
  • 比较发生与未发生自身免疫性脑炎患者的人口学与临床特征,并在发生者中按年龄组(≤4岁 vs >4岁)比较;采用多变量二元logistic回归评估危险因素。

主要发现

  • 队列A中14例(27%)随访期间发生自身免疫性脑炎,全部14例(100%)在症状出现时或之前检出神经元抗体(9例[64%]为NMDA受体抗体,5例[36%]为其他抗体)。
  • 未发生自身免疫性脑炎的37例中11例(30%)检出抗体(3例NMDAR、8例未知抗原;p<0.001)。
  • 单纯疱疹脑炎起病3周内检出抗体是自身免疫性脑炎的危险因素(OR 11.5,95%CI 2.7-48.8;p<0.001)。
  • 队列B中44例(92%)为抗体确诊自身免疫性脑炎(34例NMDAR抗体,10例其他抗体);两队列合计58例抗体确诊者中,>4岁患者常表现为精神病(18/31[58%];年幼儿童无法评估)。
  • ≤4岁组(n=27)较>4岁组(n=31):起病间隔更短(中位26天[IQR 24-32] vs 43天[25-54];p=0.0073)、舞蹈手足徐动更多(27/27[100%] vs 0/31;p<0.001)、意识下降更多(26/27[96%] vs 7/31[23%];p<0.001)、NMDAR抗体更多(24/27[89%] vs 19/31[61%];p=0.033)、1年改良Rankin量表评分更差(中位4[IQR 4-4] vs 2[2-3];p<0.0010)、癫痫更多(12/19[63%] vs 3/23[13%];p=0.001)。

临床怎么用

  • 作者认为及时诊断重要,因患者(尤其>4岁者)可对免疫治疗有反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes simplex encephalitis can trigger autoimmune encephalitis that leads to neurological worsening. We aimed to assess the frequency, symptoms, risk factors, and outcomes of this complication. METHODS: We did a prospective observational study and retrospective analysis. In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paediatricians, or infectious disease specialists in 19 secondary and tertiary Spanish centres (Cohort A). Outpatient follow-up was at 2, 6, and 12 months from onset of herpes simplex encephalitis. We studied another group of patients retrospectively, when they developed autoimmune encephalitis after herpes simplex encephalitis (Cohort B). We compared demographics and clinical features of patients who developed autoimmune encephalitis with those who did not, and in patients who developed autoimmune encephalitis we compared these features by age group (patients ≤4 years compared with patients >4 years). We also used multivariable binary logistic regression models to assess risk factors for autoimmune encephalitis after herpes simplex encephalitis. FINDINGS: Between Jan 1, 2014, and Oct 31, 2017, 54 patients with herpes simplex encephalitis were recruited to Cohort A, and 51 were included in the analysis (median age 50 years [IQR 5-68]). At onset of herpes simplex encephalitis, none of the 51 patients had antibodies to neuronal antigens; during follow-up, 14 (27%) patients developed autoimmune encephalitis and all 14 (100%) had neuronal antibodies (nine [64%] had NMDA receptor [NMDAR] antibodies and five [36%] had other antibodies) at or before onset of symptoms. The other 37 patients did not develop autoimmune encephalitis, although 11 (30%) developed antibodies (n=3 to NMDAR, n=8 to unknown antigens; p<0·001). Antibody detection within 3 weeks of herpes simplex encephalitis was a risk factor for autoimmune encephalitis (odds ratio [OR] 11·5, 95% CI 2·7-48·8; p<0·001). Between Oct 7, 2011, and Oct 31, 2017, there were 48 patients in Cohort B with new-onset or worsening neurological symptoms not caused by herpes simplex virus reactivation (median age 8·8 years [IQR 1·1-44·2]; n=27 male); 44 (92%) patients had antibody-confirmed autoimmune encephalitis (34 had NMDAR antibodies and ten had other antibodies). In both cohorts (n=58 patients with antibody-confirmed autoimmune encephalitis), patients older than 4 years frequently presented with psychosis (18 [58%] of 31; younger children not assessable). Compared with patients older than 4 years, patients aged 4 years or younger (n=27) were more likely to have shorter intervals between onset of herpes simplex encephalitis and onset of autoimmune encephalitis (median 26 days [IQR 24-32] vs 43 days [25-54]; p=0·0073), choreoathetosis (27 [100%] of 27 vs 0 of 31; p<0·001), decreased level of consciousness (26 [96%] of 27 vs seven [23%] of 31; p<0·001), NMDAR antibodies (24 [89%] of 27 vs 19 [61%] of 31; p=0·033), and worse outcome at 1 year (median modified Rankin Scale 4 [IQR 4-4] vs 2 [2-3]; p<0·0010; seizures 12 [63%] of 19 vs three [13%] of 23; p=0·001). INTERPRETATION: The results of our prospective study show that autoimmune encephalitis occurred in 27% of patients with herpes simplex encephalitis. It was associated with development of neuronal antibodies and usually presented within 2 months after treatment of herpes simplex encephalitis; the symptoms were age-dependent, and the neurological outcome was worse in young children. Prompt diagnosis is important because patients, primarily those older than 4 years, can respond to immunotherapy. FUNDING: Mutua Madrileña Foundation, Fondation de l'Université de Lausanne et Centre Hospitalier Universitaire Vaudois, Instituto Carlos III, CIBERER, National Institutes of Health, Generalitat de Catalunya, Fundació CELLEX.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018. PMID: 30049614. doi:10.1016/S1474-4422(18)30244-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。